European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 93

Vaccines Communication Immunization Documentation 93

Pharmaceutical Technology

DECEMBER 21, 2022

This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Vaccines 140

Vaccines Communication 140

European Pharmaceutical Review

JANUARY 31, 2023

A new strategy for 2023-2025 by the Medicines Patent Pool (MPP) aims to reduce access inequities, by improving the availability and affordability of health products in low- and middle-income countries (LMICs). Part of the plan includes enabling 30 million people to access MPP-licensed products each year by 2025.

Communication 83

Communication Vaccines 83

Pharmaceutical Technology

JANUARY 20, 2023

In 2020, Moderna made a net loss of $747 million while its investigational mRNA vaccines were under development. However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. billion in Covid-19 vaccine sales.

Vaccines 98

Vaccines Communication FDA 98

pharmaphorum

MARCH 12, 2021

If the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed at which vaccines for COVID-19 were discovered, developed, trialled, approved and manufactured have confirmed just how dynamic the industry can be. And those volumes will only increase.

Vaccines 111

Vaccines Pharmaceutical Companies Pharmaceutical Companies Communication 111

ISPE

OCTOBER 26, 2022

Reintroducing the liaison role of International Board members with individual Chapters and Affiliates has given us direct lines of communication to the mutual benefit of the International Board and the local groups. We defined the path forward for 2023–2025 after a final round of consultations with the Board advisors in July.

Packaging 52

Packaging Compounding Communication Vaccines 52

European Pharmaceutical Review

SEPTEMBER 29, 2023

of the draft revised Community Code provides a reduction in the basic data exclusivity period for innovative medicinal products from eight to six years, a revision which did not come as a great surprise to many. As an example, Article 81.1 The European Commission has evidently expended significant effort in developing the proposals.

Communication 79

Communication Hospitals Vaccines 79